<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>NEVANAC- nepafenac suspension </strong><br>Alcon Laboratories, Inc.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightSection">
<h1 class="Highlights"><span>RECENT MAJOR CHANGES</span></h1>
<div></div>
</div>
<div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">NEVANAC ophthalmic suspension is a nonsteroidal, anti-inflammatory prodrug indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> associated with <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery  (<a href="#INV-c075b670-56fa-4d21-93cf-c229b4f93684">1</a>). </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div><p class="Highlighta">One drop of NEVANAC ophthalmic suspension should be applied to the affected eye(s) three-times-daily beginning 1 day prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period. (<a href="#INV-3f83f1d6-357c-4f63-b2cc-72cecc224457">2</a>) </p></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div>
<p class="Highlighta">Sterile ophthalmic suspension:  0.1% (<a href="#INV-b4281a15-e4cd-4168-98e1-a01db04e0c43">3</a>) </p>
<p class="Highlighta">3 mL in a 4 mL bottle </p>
</div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><p class="Highlighta">NEVANAC is contraindicated in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients in the formula or to other NSAIDS. (<a href="#INV-682ed511-251a-49c9-aa6b-e9565ee628a2">4</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div>
<p class="Highlighta">NEVANAC has a potential for cross-sensitivity to acetylsalicylic acid, phenylacetic acid derivatives and other nonsteriodal anti-inflammatory agents (<a href="#INV-97a6d34b-5b87-4f74-befc-e10a4b1a5d2f">5.1</a>) </p>
<p class="Highlighta">NEVANAC may increase <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span> due to increased thrombocyte aggregation (<a href="#INV-8cdffa9f-16ee-4dee-9e9b-944f6e8e0491">5.2</a>) </p>
<p class="Highlighta">NEVANAC may slow or delay healing (<a href="#INV-80f8cedc-af0f-43b9-91be-2c044abac23c">5.3</a>) and may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span> (<a href="#INV-9effef27-fa77-4ae7-811f-d5f06e8512c9">5.4</a>) </p>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div><p class="Highlighta">Most common adverse reactions (5 to 10%) are capsular opacity, decreased visual acuity, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and sticky sensation. <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span> and ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (<a href="#INV-effaea4b-a83c-4875-8a72-b77af02d0d6e">6.1</a>) </p></div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
</div>
<div></div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
<div></div>
<div></div>
<div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION.</p>
<p class="HighlightsRevision">Revised: 1/2008</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-2" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-3" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-3.1" class="toc">2.1	Recommended Dosing</a></h2>
<h2><a href="#section-3.2" class="toc">2.2	Use with Other Topical Ophthalmic Medications</a></h2>
<h1><a href="#section-4" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-5" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-6" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">5.1	Cross-Sensitivity</a></h2>
<h2><a href="#section-6.2" class="toc">5.2	<span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></a></h2>
<h2><a href="#section-6.3" class="toc">5.3	Delayed Healing</a></h2>
<h2><a href="#section-6.4" class="toc">5.4	Corneal Effects</a></h2>
<h2><a href="#section-6.5" class="toc">5.5	Contact Lens Wear</a></h2>
<h1><a href="#section-7" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-7.1" class="toc">6.1	Ocular Adverse Reactions</a></h2>
<h2><a href="#section-7.2" class="toc">6.2	Non-Ocular Adverse Reactions</a></h2>
<h1><a href="#section-8" class="toc">7 DRUG INTERACTIONS</a></h1>
<h1><a href="#section-9" class="toc">8 USE IN SPECIFIC POPULATIONS SECTION</a></h1>
<h2><a href="#section-9.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-9.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-9.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-9.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-10" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-11" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-11.1" class="toc">12.1 Mechanism of Action</a></h2>
<h2><a href="#section-11.2" class="toc">12.3 Pharmacokinetics</a></h2>
<h1><a href="#section-12" class="toc">13 NONCLINICAL TOXICOLOGY SECTION</a></h1>
<h2><a href="#section-12.1" class="toc">13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</a></h2>
<h1><a href="#section-13" class="toc">14 CLINICAL STUDIES</a></h1>
<h1><a href="#section-14" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-15" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<h2><a href="#section-15.1" class="toc">17.1	Slow or Delayed Healing</a></h2>
<h2><a href="#section-15.2" class="toc">17.2	Avoiding Contamination of the Product</a></h2>
<h2><a href="#section-15.3" class="toc">17.3	Contact Lens Wear</a></h2>
<h2><a href="#section-15.4" class="toc">17.4	Intercurrent Ocular Conditions</a></h2>
<h2><a href="#section-15.5" class="toc">17.5	Concomitant Topical Ocular Therapy</a></h2>
<h2><a href="#section-15.6" class="toc">17.6	Shake Well Before Use</a></h2>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="INV-c075b670-56fa-4d21-93cf-c229b4f93684"></a><a name="section-2"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First"><a name="INV-ffee3217-578b-421f-846c-4348fc34ef7e"></a>NEVANAC<span class="Sup">®</span> ophthalmic suspension is indicated for the treatment of <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> and <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> associated with <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="INV-3f83f1d6-357c-4f63-b2cc-72cecc224457"></a><a name="section-3"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<div class="Section">
<a name="INV-8fc66fec-dc0a-4f7c-a9ed-352b59682edf"></a><a name="section-3.1"></a><p></p>
<h2>2.1	Recommended Dosing</h2>
<p class="First"><a name="INV-12c5ab19-65ae-4335-8f2d-21ab214b6336"></a>One drop of NEVANAC should be applied to the affected eye(s) three-times-daily beginning 1 day prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, continued on the day of surgery and through the first 2 weeks of the postoperative period.</p>
</div>
<div class="Section">
<a name="INV-4bc3a5b6-6b8f-44fa-9198-de00f4caa429"></a><a name="section-3.2"></a><p></p>
<h2>2.2	Use with Other Topical Ophthalmic Medications</h2>
<p class="First"><a name="INV-451f48f0-07e8-479d-b24c-f45a482a7ed6"></a>NEVANAC<span class="Sup">®</span> may be administered in conjunction with other topical ophthalmic medications such as beta-blockers, carbonic anhydrase inhibitors, alpha-agonists, cycloplegics, and mydriatics.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="INV-b4281a15-e4cd-4168-98e1-a01db04e0c43"></a><a name="section-4"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First"><a name="INV-0ca458bb-897c-45aa-a589-3f50ee6eafbc"></a>Sterile ophthalmic suspension: 0.1%</p>
<p><a name="INV-1a653a10-4925-426b-a12d-6d9f06ac814f"></a>3  mL in a 4 mL bottle</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="INV-682ed511-251a-49c9-aa6b-e9565ee628a2"></a><a name="section-5"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First"><a name="INV-b116b2ea-2797-466e-a034-88f6fa95a338"></a>NEVANAC<span class="Sup">®</span> is contraindicated in patients with previously demonstrated <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to any of the ingredients in the formula or to other NSAIDS.</p>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="INV-9e735be4-6122-486f-a299-ca99bb1a8110"></a><a name="section-6"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section">
<a name="INV-97a6d34b-5b87-4f74-befc-e10a4b1a5d2f"></a><a name="section-6.1"></a><p></p>
<h2>5.1	Cross-Sensitivity</h2>
<p class="First"><a name="INV-c92d6600-97ec-4aa8-a98f-128b5fe74a68"></a>There is a potential for cross-sensitivity of nepafenac to acetylsalicylic acid, phenylacetic acid derivatives, and other NSAIDs.  Therefore, caution should be used when treating individuals who have previously exhibited sensitivities to these drugs.</p>
</div>
<div class="Section">
<a name="INV-8cdffa9f-16ee-4dee-9e9b-944f6e8e0491"></a><a name="section-6.2"></a><p></p>
<h2>5.2	<span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">Bleeding Time</span></h2>
<p class="First"><a name="INV-c948303e-77a3-4629-9af0-cb4f33b9ada0"></a>With some nonsteroidal anti-inflammatory drugs including NEVANAC<span class="Sup">®</span>, there exists the potential for increased <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span> due to interference with thrombocyte aggregation. There have been reports that ocularly applied nonsteroidal anti-inflammatory drugs may cause increased <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> of ocular tissues (including <span class="product-label-link" type="condition" conceptid="432904" conceptname="Hyphema">hyphemas</span>) in conjunction with ocular surgery.</p>
<p><a name="INV-53a23af5-8b07-4d0c-8f7d-8b188cb38c5b"></a>It is recommended that NEVANAC<span class="Sup">®</span> ophthalmic suspension be used with caution in patients with known <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">bleeding</span> tendencies or who are receiving other medications which may prolong <span class="product-label-link" type="condition" conceptid="4219104" conceptname="Bleeding time">bleeding time</span>.</p>
</div>
<div class="Section">
<a name="INV-80f8cedc-af0f-43b9-91be-2c044abac23c"></a><a name="section-6.3"></a><p></p>
<h2>5.3	Delayed Healing</h2>
<p class="First"><a name="INV-7a608ff8-5b2e-453e-aeae-bef8224db689"></a>Topical nonsteroidal anti-inflammatory drugs (NSAIDs) including NEVANAC<span class="Sup">®</span>, may slow or delay healing. Topical corticosteroids are also known to slow or delay healing. Concomitant use of topical NSAIDs and topical steroids may increase the potential for healing problems.</p>
</div>
<div class="Section">
<a name="INV-9effef27-fa77-4ae7-811f-d5f06e8512c9"></a><a name="section-6.4"></a><p></p>
<h2>5.4	Corneal Effects</h2>
<p class="First"><a name="INV-6c687bf4-af1d-43c9-ac5f-c907a4829c49"></a>Use of topical NSAIDs may result in <span class="product-label-link" type="condition" conceptid="374035" conceptname="Keratitis">keratitis</span>. In some susceptible patients, continued use of topical NSAIDs may result in epithelial breakdown, <span class="product-label-link" type="condition" conceptid="4307537" conceptname="Corneal thinning">corneal thinning</span>, <span class="product-label-link" type="condition" conceptid="4179918" conceptname="Corneal erosion">corneal erosion</span>, <span class="product-label-link" type="condition" conceptid="373202" conceptname="Corneal ulcer">corneal ulceration</span> or <span class="product-label-link" type="condition" conceptid="4326414" conceptname="Perforation of cornea">corneal perforation</span>. These events may be sight threatening. Patients with evidence of corneal epithelial breakdown should immediately discontinue use of topical NSAIDs including NEVANAC<span class="Sup">®</span> and should be closely monitored for corneal health.</p>
<p><a name="INV-c9657fd9-fc4f-4411-b734-461da1fae04d"></a>Postmarketing experience with topical NSAIDs suggests that patients with complicated ocular surgeries, corneal denervation, corneal epithelial defects, <span class="product-label-link" type="condition" conceptid="201820" conceptname="Diabetes mellitus">diabetes</span> mellitus, ocular surface diseases (e.g., <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye syndrome</span>), <span class="product-label-link" type="condition" conceptid="80809" conceptname="Rheumatoid arthritis">rheumatoid arthritis</span>, or repeat ocular surgeries within a short period of time may be at increased risk for corneal adverse events which may become sight threatening. Topical NSAIDs should be used with caution in these patients.</p>
<p><a name="INV-cbfa074c-4d3d-4e45-96e3-a964a7ffe201"></a>Postmarketing experience with topical NSAIDs also suggests that use more than 1 day prior to surgery or use beyond 14 days post surgery may increase patient risk for occurrence and severity of corneal adverse events.</p>
</div>
<div class="Section">
<a name="INV-87b64627-0396-4d96-b9a0-871acd705a3c"></a><a name="section-6.5"></a><p></p>
<h2>5.5	Contact Lens Wear</h2>
<p class="First"><a name="INV-bdbea249-aa51-421c-a372-94213ca27b3b"></a>NEVANAC should not be administered while using contact lenses.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="INV-0e28deaf-2811-4c31-b715-7f6d6647e56c"></a><a name="section-7"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First"><a name="INV-5161edd3-337e-4131-a1f9-bc7275f25e12"></a>Because clinical studies are conducted under widely varying conditions, adverse reaction rates observed in the clinical studies of a drug cannot be directly compared to the rates in the clinical studies of another drug and may not reflect the rates observed in practice.</p>
<div class="Section">
<a name="INV-effaea4b-a83c-4875-8a72-b77af02d0d6e"></a><a name="section-7.1"></a><p></p>
<h2>6.1	Ocular Adverse Reactions</h2>
<p class="First"><a name="INV-2cd1b077-a3ba-43cc-8a75-cdc339d4eae9"></a>The most frequently reported ocular adverse events following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery were capsular opacity, decreased visual acuity, foreign body sensation, <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span>, and sticky sensation. These events occurred in approximately 5 to 10% of patients.</p>
<p><a name="INV-5929177f-c7f5-4615-86fd-b6c3e3930af7"></a>Other ocular adverse events occurring at an incidence of approximately 1 to 5% included <span class="product-label-link" type="condition" conceptid="380117" conceptname="Conjunctival edema">conjunctival edema</span>, <span class="product-label-link" type="condition" conceptid="377875" conceptname="Idiopathic corneal edema">corneal edema</span>, <span class="product-label-link" type="condition" conceptid="373204" conceptname="Conjunctival xerosis">dry eye</span>, lid margin crusting, <span class="product-label-link" type="condition" conceptid="372912" conceptname="Visual discomfort">ocular discomfort</span>, <span class="product-label-link" type="condition" conceptid="442546" conceptname="Red eye">ocular hyperemia</span>, <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span>, ocular <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="4260194" conceptname="Photophobia">photophobia</span>, tearing and <span class="product-label-link" type="condition" conceptid="4202518" conceptname="Vitreous detachment">vitreous detachment</span>.</p>
<p><a name="INV-344f71ee-db8a-402d-8a1c-8065f4fb3ce8"></a>Some of these events may be the consequence of the <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgical procedure.</p>
</div>
<div class="Section">
<a name="INV-9035b724-c249-4607-8fed-891bd72e7ec2"></a><a name="section-7.2"></a><p></p>
<h2>6.2	Non-Ocular Adverse Reactions</h2>
<p class="First"><a name="INV-4546d808-47ac-45a3-b255-b3de7b65689c"></a>Non-ocular adverse events reported at an incidence of 1 to 4% included <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>/<span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="4283893" conceptname="Sinusitis">sinusitis</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="INV-9e6200b8-731b-49d0-998f-f04331210a8b"></a><a name="section-8"></a><p></p>
<h1>7 DRUG INTERACTIONS</h1>
<p class="First"><a name="INV-34648e2c-190f-4399-84b0-662a915dbbef"></a>Nepafenac at concentrations up to 300 ng/mL did not inhibit the in vitro metabolism of 6 specific marker substrates of cytochrome P450 (CYP) isozymes (CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4). Therefore, drug-drug interactions involving CYPmediated metabolism of concomitantly administered drugs are unlikely. Drug-drug interactions mediated by protein binding are also unlikely.</p>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="INV-e752dd86-3204-4538-967a-cb820d38f935"></a><a name="section-9"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS SECTION</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="INV-76fdaed4-df3a-4115-948c-f136c038a089"></a><a name="section-9.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section">
<a name="INV-7bed3a23-832e-442c-8925-ce98a45ce396"></a><a name="section-9.1.1"></a><p></p>
<h3>Teratogenic Effects.</h3>
<p class="First"><a name="INV-5e223d0d-976c-488f-980e-118fa9e28c66"></a>Pregnancy Category C: Reproduction studies performed with nepafenac in rabbits and rats at oral doses up to 10 mg/kg/day have revealed no evidence of <span class="product-label-link" type="condition" conceptid="4240324" conceptname="Teratogenesis">teratogenicity</span> due to nepafenac, despite the induction of maternal toxicity. At this dose, the animal plasma exposure to nepafenac and amfenac was approximately 260 and 2400 times human plasma exposure at the recommended human topical ophthalmic dose for rats and 80 and 680 times human plasma exposure for rabbits, respectively. In rats, maternally toxic doses ≥ 10 mg/kg were associated with dystocia, increased postimplantation loss, reduced fetal weights and growth, and reduced fetal survival.</p>
<p><a name="INV-b72703bc-21f9-4690-be51-61eb3d382158"></a>Nepafenac has been shown to cross the placental barrier in rats. There are no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, NEVANAC<span class="Sup">®</span> should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.</p>
</div>
<div class="Section">
<a name="INV-575c221d-3fca-41d1-867b-16988ecdb54a"></a><a name="section-9.1.2"></a><p></p>
<h3>Non-teratogenic Effects.</h3>
<p class="First"><a name="INV-e40213de-f0cd-48c9-802b-fd96f0a3a816"></a>Because of the known effects of prostaglandin biosynthesis inhibiting drugs on the fetal cardiovascular system (closure of the ductus arteriosus), the use of NEVANAC<span class="Sup">®</span> during late pregnancy should be avoided.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="INV-d5a3ad7e-b2c7-4bff-a183-7bfb1edc49f4"></a><a name="section-9.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First"><a name="INV-77c80f3f-2ac4-49b4-8b1d-41dc733b1d49"></a>NEVANAC<span class="Sup">®</span> is excreted in the milk of lactating rats. It is not known whether this drug is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when NEVANAC<span class="Sup">®</span> ophthalmic suspension is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="INV-6894cdc6-fd6e-42e1-9d67-ac8057eda1a4"></a><a name="section-9.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First"><a name="INV-15170daf-d86e-4b77-8a45-1f49dea4d40a"></a>The safety and effectiveness of NEVANAC<span class="Sup">®</span> in pediatric patients below the age of 10 years have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="INV-f349ecb0-ca78-4251-9167-f1296de580e2"></a><a name="section-9.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First"><a name="INV-f12fc71c-da7b-44d5-be69-5e5c1d3cf98e"></a>No overall differences in safety and effectiveness have been observed between elderly and younger patients.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="INV-a9854963-9bd9-4cd0-a847-0357f84c4dd6"></a><a name="section-10"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First"><a name="INV-fe513f2f-d181-44f9-81a7-13ae260981a5"></a>NEVANAC<span class="Sup">®</span> (nepafenac ophthalmic suspension) 0.1% is a sterile, topical, nonsteroidal anti-inflammatory (NSAID) prodrug for ophthalmic use. Each mL of NEVANAC<span class="Sup">®</span> suspension contains 1 mg of nepafenac. Nepafenac is designated chemically as 2-amino-3-benzoylbenzeneacetamide with an empirical formula of C<span class="Sub">15</span>H<span class="Sub">14</span>N<span class="Sub">2</span>O<span class="Sub">2</span>. The structural formula of nepafenac is:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=4c9ae54a-97a0-4613-a092-31e86d9bfc91&amp;name=Nepafenac.JPG"></div>
<p><a name="INV-02790a33-d0c1-46c4-b3a7-f97af3e78416"></a>Nepafenac is a yellow crystalline powder. The molecular weight of nepafenac is 254.28. NEVANAC<span class="Sup">®</span> ophthalmic suspension is supplied as a sterile, aqueous 0.1% suspension with a pH approximately of 7.4.</p>
<p><a name="INV-dfeb0b71-45a5-4228-9c2a-04b34b26100a"></a>The <span class="product-label-link" type="condition" conceptid="4197115" conceptname="Osmotic pressure">osmolality</span> of NEVANAC<span class="Sup">®</span> ophthalmic suspension is approximately 305 mOsmol/kg.</p>
<p><a name="INV-0cf499e9-8150-4a32-8f05-bd713c5d92e1"></a>Each mL of NEVANAC<span class="Sup">®</span> contains: Active: nepafenac 0.1% Inactives: mannitol, carbomer 974P, sodium chloride, tyloxapol, edetate disodium, benzalkonium chloride 0.005% (preservative), sodium hydroxide and/or hydrochloric acid to adjust pH and purified water, USP.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="INV-3256fbba-6d66-4870-9ebf-b18a77833c66"></a><a name="section-11"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="INV-dbababf9-9eec-4faf-8523-4e2b15eab6f3"></a><a name="section-11.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First"><a name="INV-71c9198d-859f-4dc0-a292-212a7c3346ab"></a>Nepafenac (0.1%) is a nonsteroidal anti-inflammatory and analgesic prodrug. After topical ocular dosing, nepafenac penetrates the cornea and is converted by ocular tissue hydrolases to amfenac, a nonsteroidal anti-inflammatory drug. Amfenac is thought to inhibit the action of prostaglandin H synthase (cyclooxygenase), an enzyme required for prostaglandin production.</p>
</div>
<div class="Section" data-sectionCode="43682-4">
<a name="INV-025c0518-6d6b-482d-aa44-5058a65741ad"></a><a name="section-11.2"></a><p></p>
<h2>12.3 Pharmacokinetics</h2>
<p class="First"><a name="INV-1edd82ea-d25a-46f1-9662-3a30516eac84"></a>Gender: Data in healthy subjects indicate no clinically relevant or significant gender difference in the steady-state pharmacokinetics of amfenac following three-times-daily dosing of NEVANAC<span class="Sup">®</span>.</p>
<p><a name="INV-2017da9e-f585-4689-a174-7df1cabf3cdf"></a>Low but quantifiable plasma concentrations of nepafenac and amfenac were observed in the majority of subjects 2 and 3 hours postdose, respectively, following bilateral topical ocular three-times-daily dosing of nepafenac ophthalmic suspension, 0.1%. The mean steady-state Cmax for nepafenac and for amfenac were 0.310 ± 0.104 ng/ml and 0.422 ± 0.121 ng/ml, respectively, following ocular administration.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="INV-0a0ba607-e328-42d8-98fb-cc761d0c2ccf"></a><a name="section-12"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY SECTION</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="INV-e360ea1a-ada7-4113-970d-89317bacc2ac"></a><a name="section-12.1"></a><p></p>
<h2>13.1 Carcinogenesis and Mutagenesis and Impairment of Fertility</h2>
<p class="First"><a name="INV-74dc252a-bdac-4c90-bd8c-1abc195acb04"></a>Nepafenac has not been evaluated in long-term carcinogenicity studies. Increased chromosomal aberrations were observed in Chinese hamster ovary cells exposed in vitro to nepafenac suspension. Nepafenac was not mutagenic in the Ames assay or in the mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> forward mutation assay. Oral doses up to 5,000 mg/kg did not result in an increase in the formation of micronucleated polychromatic erythrocytes in vivo in the mouse micronucleus assay in the bone marrow of mice.</p>
<p><a name="INV-7cba0c26-4cee-41b8-b307-32b7e1a06d43"></a>Nepafenac did not impair fertility when administered orally to male and female rats at 3 mg/kg (approximately 90 and 380 times the plasma exposure to the parent drug, nepafenac, and the active metabolite, amfenac, respectively, at the recommended human topical ophthalmic dose).</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="INV-2813d852-331d-42b3-84de-8264ef607aab"></a><a name="section-13"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First"><a name="INV-6a213001-8770-4e51-903b-6420c56590ee"></a>In two double-masked, randomized clinical trials in which patients were dosed three-times-daily beginning one day prior to <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery, continued on the day of surgery and for the first two weeks of the postoperative period, NEVANAC<span class="Sup">®</span> ophthalmic suspension demonstrated clinical efficacy, compared to its vehicle in treating postoperative <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span>.</p>
<p><a name="INV-dec78fbe-e4c9-46a8-b403-cd5202ffda55"></a>Patients treated with NEVANAC<span class="Sup">®</span> ophthalmic suspension were less likely to have <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> and measurable signs of <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (cells and flare) in the early postoperative period through the end of treatment than those treated with its vehicle.</p>
<p><a name="INV-9dce8872-f40c-4da9-a468-5f49617a4c52"></a>For <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> in both studies a significantly higher percentage of patients (approximately 80%) in the nepafenac group reported no <span class="product-label-link" type="condition" conceptid="379031" conceptname="Pain in eye">ocular pain</span> on the day following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery (Day 1) compared to those in the vehicle group (approximately 50%).</p>
<p><a name="INV-16234bf0-5afa-4992-aa9b-0933cbd2419d"></a>Results from clinical studies indicated that NEVANAC<span class="Sup">®</span> has no significant effect upon intraocular pressure; however, changes in intraocular pressure may occur following <span class="product-label-link" type="condition" conceptid="375545" conceptname="Cataract">cataract</span> surgery.</p>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="INV-9c4f2aea-fa40-426e-abcd-cf4fbcc6202b"></a><a name="section-14"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First"><a name="INV-7b8b6043-6491-48f5-9dc6-224fb174404c"></a>NEVANAC<span class="Sup">®</span> (nepafenac ophthalmic suspension) is supplied in a natural, oval, low density polyethylene DROP-TAINER® dispenser with a natural low density polyethylene dispensing plug and gray polypropylene cap. Tamper evidence is provided with a shrink band around the closure and neck area of the package.</p>
<p><a name="INV-00244904-ebc2-422c-a498-9e1bef992a05"></a>3 mL in 4 mL bottle 	NDC 0065-0002-03</p>
<p><a name="INV-a5349afb-775a-4c5c-a775-6e85df7decb1"></a><span class="Bold">Storage:</span> Store at 2 - 25˚C (36 - 77˚F).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="INV-b07beee6-0c2d-48f9-9e4e-c60e8ab76b40"></a><a name="section-15"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<div class="Section">
<a name="INV-11577535-42ca-48f4-8546-c57b9cc8e5cb"></a><a name="section-15.1"></a><p></p>
<h2>17.1	Slow or Delayed Healing</h2>
<p class="First"><a name="INV-b0acbfe3-8eb0-48e4-9aa4-9dc706fabf2e"></a>Patients should be informed of the possibility that slow or delayed healing may occur while using nonsteroidal anti-inflammatory drugs (NSAIDs).</p>
</div>
<div class="Section">
<a name="INV-d9f9e758-9671-43e4-bee1-dd2cf32576e5"></a><a name="section-15.2"></a><p></p>
<h2>17.2	Avoiding Contamination of the Product</h2>
<p class="First"><a name="INV-9e773e63-649b-4272-8925-0b2a192dafd3"></a>Patients should be instructed to avoid allowing the tip of the dispensing container to contact the eye or surrounding structures because this could cause the tip to become contaminated by common bacteria known to cause ocular <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>.  Serious damage to the eye and subsequent <span class="product-label-link" type="condition" conceptid="377551" conceptname="Blind hypertensive eye">loss of vision</span> may result from using contaminated solutions.</p>
</div>
<div class="Section">
<a name="INV-aec533d6-2a3c-404a-a182-60fbdcdd135f"></a><a name="section-15.3"></a><p></p>
<h2>17.3	Contact Lens Wear</h2>
<p class="First"><a name="INV-d3b1446e-cc8e-459d-b6e6-5f0b8b731613"></a>NEVANAC<span class="Sup">®</span> should not be administered while wearing contact lens.</p>
</div>
<div class="Section">
<a name="INV-012eca4b-0359-448a-9ede-d294231a2cbe"></a><a name="section-15.4"></a><p></p>
<h2>17.4	Intercurrent Ocular Conditions</h2>
<p class="First"><a name="INV-4bc99ddf-a2d1-44aa-84fa-4d542c6c3ad3"></a>Patients should be advised that if they develop an intercurrent ocular condition (e.g., <span class="product-label-link" type="condition" conceptid="433633" conceptname="Late effect of superficial injury">trauma</span>, or <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infection</span>) or have ocular surgery, they should immediately seek their physician’s advice concerning the continued use of the multi-dose container.</p>
</div>
<div class="Section">
<a name="INV-1f799411-9bcb-4dfb-913a-9ceddcabedd0"></a><a name="section-15.5"></a><p></p>
<h2>17.5	Concomitant Topical Ocular Therapy</h2>
<p class="First"><a name="INV-da861f28-5926-4b87-bd81-5cf5684801d3"></a>If more than one topical ophthalmic medication is being used, the medicines must be administered at least 5 minutes apart.</p>
</div>
<div class="Section">
<a name="INV-47c003f9-d224-4aee-b748-7cde56ee2930"></a><a name="section-15.6"></a><p></p>
<h2>17.6	Shake Well Before Use</h2>
<p class="First"><a name="INV-4a90414d-f484-4ed6-8b30-5dc64e6b7c88"></a>Patients should be advised to shake the bottle well.</p>
<p><a name="INV-b618ce12-dcf2-4f29-bb54-d21fe2b58248"></a>U.S. Patent No; 5,475,034</p>
<p><a name="INV-2aeee082-b6e6-46a0-b01d-bfc704be7703"></a><span class="Bold">ALCON®</span></p>
<p><a name="INV-5476680b-e235-451f-8ed3-dbfdbb4b6187"></a>ALCON LABORATORIES, INC.</p>
<p><a name="INV-84f50beb-6efc-4e66-8e0a-7e655edc7b99"></a>Fort Worth, Texas 76134 USA</p>
<p><a name="INV-0362a2d6-fc19-402a-8b66-68b8a5f49ee6"></a>©	2007 Alcon, Inc.</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>NEVANAC 		
					</strong><br><span class="contentTableReg">nepafenac suspension</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem"></td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0065-0002</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">OPHTHALMIC</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>nepafenac</strong> (nepafenac) </td>
<td class="formItem"></td>
<td class="formItem">1 mg  in 1 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>mannitol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>carbomer 974P</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium chloride</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>tyloxapol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>edetate disodium</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>benzalkonium chloride</strong></td>
<td class="formItem">0.05 mg  in 1 mL</td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sodium hydroxide and/or hydrochloric acid</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0065-0002-03</td>
<td class="formItem">3 mL in 1 BOTTLE, PLASTIC</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Alcon Laboratories, Inc.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 1/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>80A2F7A6-5B85-813D-EB99-3B8E669328C8</div>
<div>Set id: 4c9ae54a-97a0-4613-a092-31e86d9bfc91</div>
<div>Version: 1</div>
<div>Effective Time: 20080117</div>
</div>
</div> <div class="DistributorName">Alcon Laboratories, Inc.</div></p>
</body></html>
